Research summaries for everyoneNot medical advice
Ipamorelin research reference vial, Elevated Pharma

Research reference · Hormones

Ipamorelin

Ipamorelin is a synthetic pentapeptide growth-hormone secretagogue, first described in 1998 as selective for growth hormone release.

Published by Elevated Pharma ·

HormonesHuman research literature

Identity

What is Ipamorelin?

A synthetic pentapeptide ghrelin-receptor agonist (NNC 26-0161).

Research context

What has Ipamorelin been studied for?

Human data are limited to pharmacokinetic modeling in volunteers and one phase 2 trial in postoperative ileus.

Evidence boundary

What does the research not show?

A small clinical literature does not establish broad safety or effectiveness.

U.S. status · November 7, 2026

Is Ipamorelin FDA-approved?

Not FDA-approved. Ipamorelin was not on FDA’s 2026 compounding advisory agendas.

Key studies

The main Ipamorelin research

Selected from PubMed: human trials first, then reviews, then foundational laboratory work. Each finding applies to the material and setting studied.

Search all 51 PubMed records for Ipamorelin · Counts and selections checked November 7, 2026.

Reference identifiers

Ipamorelin identity data

Database identity describes the reference substance, not any specific material or lot.

Primary name
Ipamorelin
Also indexed as
NNC 26-0161
Molecular formula
C38H49N9O5
Molecular mass
711.9 g/mol
PubChem CID
9831659

Official & primary sources

Regulatory and database records

Citation does not imply an Elevated Pharma partnership or endorsement.